251
|
Ali M, Amon M, Bender V, Bolte A, Separovic F, Benson H, Manolios N. Cyclization enhances function of linear anti-arthritic peptides. Clin Immunol 2013; 150:121-33. [PMID: 24207019 DOI: 10.1016/j.clim.2013.10.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 08/19/2013] [Accepted: 10/02/2013] [Indexed: 12/30/2022]
Abstract
This study describes the biophysical and immunomodulatory features of a cyclic peptide termed C1 which consists of alternating d-, l-amino acids and is capable of inhibiting IL-2 production in vitro and reducing the induction and extent of T-cell mediated inflammation in animal models. Solid-state nuclear magnetic resonance demonstrates that the peptide orders the lipid bilayer, suggesting a transmembrane orientation, and this is supported by surface plasmon resonance indicating strong binding affinity of C1 to model membranes. In vitro cell viability and proliferation assays show that C1 does not disrupt the integrity of cell surface membranes. Permeation studies of C1 and analogs across human epidermis cells show that the stability and skin permeability are enhanced by cyclization. Treatment with C1 in an asthma and in an arthritis animal model resulted in a suppressed immune response. Cyclization may be a useful means of enhancing biological linear peptide activity and improving delivery.
Collapse
|
252
|
Nagao K, Hata M, Tanaka K, Takechi Y, Nguyen D, Dhanasekaran P, Lund-Katz S, Phillips MC, Saito H. The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles. Biochim Biophys Acta Mol Cell Biol Lipids 2013; 1841:80-7. [PMID: 24120703 DOI: 10.1016/j.bbalip.2013.10.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Revised: 09/07/2013] [Accepted: 10/01/2013] [Indexed: 12/20/2022]
Abstract
Apolipoprotein A-I (apoA-I) accepts cholesterol and phospholipids from ATP-binding cassette transporter A1 (ABCA1)-expressing cells to form high-density lipoprotein (HDL). Human apoA-I has two tertiary structural domains and the C-terminal domain (approximately amino acids 190-243) plays a key role in lipid binding. Although the high lipid affinity region of the C-terminal domain of apoA-I (residues 223-243) is essential for the HDL formation, the function of low lipid affinity region (residues 191-220) remains unclear. To evaluate the role of residues 191-220, we analyzed the structure, lipid binding properties, and HDL formation activity of Δ191-220 apoA-I, in comparison to wild-type and Δ223-243 apoA-I. Although deletion of residues 191-220 has a slight effect on the tertiary structure of apoA-I, the Δ191-220 variant showed intermediate behavior between wild-type and Δ223-243 regarding the formation of hydrophobic sites and lipid interaction through the C-terminal domain. Physicochemical analysis demonstrated that defective lipid binding of Δ191-220 apoA-I is due to the decreased ability to form α-helix structure which provides the energetic source for lipid binding. In addition, the ability to form HDL particles in vitro and induce cholesterol efflux from ABCA1-expressing cells of Δ191-220 apoA-I was also intermediate between wild-type and Δ223-243 apoA-I. These results suggest that despite possessing low lipid affinity, residues 191-220 play a role in enhancing the ability of apoA-I to bind to and solubilize lipids by forming α-helix upon lipid interaction. Our results demonstrate that the combination of low lipid affinity region and high lipid affinity region of apoA-I is required for efficient ABCA1-dependent HDL formation.
Collapse
|
253
|
Wacker M. Nanocarriers for intravenous injection--the long hard road to the market. Int J Pharm 2013; 457:50-62. [PMID: 24036012 DOI: 10.1016/j.ijpharm.2013.08.079] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Revised: 08/27/2013] [Accepted: 08/28/2013] [Indexed: 12/19/2022]
Abstract
Nanodispersed drug delivery systems for the intravenous injection have successfully overcome the hurdle of drug approval in the European Union and the United States. Although there is a need for highly advanced nanocarrier devices they have not been the result of a rational formulation design but were developed as stand-alone products in a long chain of case-by-case studies. This review focuses on aspects in development, composition, and manufacture of these innovative dosage forms that are relevant for the translation into new drug products.
Collapse
|
254
|
Tandberg DJ, Gee NG, Chino JP, D'Amico TA, Ready NE, Coleman RE, Kelsey CR. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? J Thorac Cardiovasc Surg 2013; 146:796-801. [PMID: 23870158 DOI: 10.1016/j.jtcvs.2013.05.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Revised: 05/09/2013] [Accepted: 05/23/2013] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Many patients with non-small cell lung cancer have positive mediastinal lymph nodes on preoperative positron emission tomography (PET) but do not have mediastinal involvement after surgery. The prognostic significance of this discordance was assessed. METHODS This Institutional Review Board-approved study evaluated patients treated with upfront surgery at Duke Cancer Institute (Durham, NC) for non-small cell lung cancer from 1995 to 2008. Those staged with PET with pN0-1 disease after negative invasive mediastinal assessment were included. Mediastinal lymph nodes were scored as positive or negative based on visual analysis of the preoperative PET. Clinical outcomes of the PET-positive and PET-negative cohorts were estimated using the Kaplan-Meier method and compared using a log-rank test. Prognostic factors were assessed using a multivariate analysis. RESULTS A total of 547 patients were assessed, of whom 105 (19%) were PET positive in the mediastinum. The median number of mediastinal lymph node stations sampled was 4 (range, 1-9). The 5-year risk of local recurrence was 26% in PET-positive versus 21% in PET-negative patients (P = .50). Patterns of local failure were similar between the 2 groups. Distant recurrence (35% vs 29%; P = .63) and overall survival (44% vs 54%; P = .52) were comparable for PET-positive and PET-negative patients. On multivariate analysis, a positive PET was not significant for local recurrence (hazard ratio [HR], 1; P = 1), distant recurrence (HR, 0.82; P = .42), or overall survival (HR, 1.08; P = .62). CONCLUSIONS Patients with positive mediastinal lymph nodes on preoperative PET, but negative on histologic analysis, are not at increased risk of disease recurrence. Pathologic staging remains the standard.
Collapse
|
255
|
Ugarte-Uribe B, Grijalvo S, Busto JV, Martín C, Eritja R, Goñi FM, Alkorta I. Double-tailed lipid modification as a promising candidate for oligonucleotide delivery in mammalian cells. Biochim Biophys Acta Gen Subj 2013; 1830:4872-84. [PMID: 23800579 DOI: 10.1016/j.bbagen.2013.06.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 05/31/2013] [Accepted: 06/13/2013] [Indexed: 12/17/2022]
Abstract
BACKGROUND The potential use of nucleic acids as therapeutic drugs has triggered the quest for oligonucleotide conjugates with enhanced cellular permeability. To this end, the biophysical aspects of previously reported potential lipid oligodeoxyribonucleotide conjugates were studied including its membrane-binding properties and cellular uptake. METHODS These conjugates were fully characterized by MALDI-TOF mass spectrometry and HPLC chromatography. Their ability to insert into lipid model membrane systems was evaluated by Langmuir balance and confocal microscopy followed by the study of the internalization of a lipid oligodeoxyribonucleotide conjugate bearing a double-tail lipid modification (C28) into different cell lines by confocal microscopy and flow cytometry. This compound was also compared with other lipid containing conjugates and with the classical lipoplex formulation using Transfectin as transfection reagent. RESULTS This double-tail lipid modification showed better incorporation into both lipid model membranes and cell systems. Indeed, this lipid conjugation was capable of inserting the oligodeoxyribonucleotide into both liquid-disordered and liquid-ordered domains of model lipid bilayer systems and produced an enhancement of oligodeoxyribonucleotide uptake in cells, even better than the effect caused by lipoplexes. In addition, in β2 integrin (CR3) expressing cells this receptor was directly involved in the enhanced internalization of this compound. CONCLUSIONS All these features confirm that the dual lipid modification (C28) is an excellent modification for enhancing nucleic acid delivery without altering their binding properties. GENERAL SIGNIFICANCE Compared to the commercial lipoplex approach, oligodeoxyribonucleotide conjugation with C28 dual lipid modification seems to be promising to improve oligonucleotide delivery in mammalian cells.
Collapse
|
256
|
Vanderhoek M, Perlman SB, Jeraj R. Impact of different standardized uptake value measures on PET-based quantification of treatment response. J Nucl Med 2013; 54:1188-94. [PMID: 23776199 DOI: 10.2967/jnumed.112.113332] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
UNLABELLED PET-based treatment response studies typically measure the change in the standardized uptake value (SUV) to quantify response. The relative changes of different SUV measures, such as maximum, peak, mean, or total SUVs (SUV(max), SUV(peak), SUV(mean), or SUV(total), respectively), are used across the literature to classify patients into response categories, with quantitative thresholds separating the different categories. We investigated the impact of different SUV measures on the quantification and classification of PET-based treatment response. METHODS Sixteen patients with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor, resulting in a variety of responses. Using the cellular proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT), we acquired whole-body PET/CT scans at baseline, during treatment, and after treatment. The highest (18)F-FLT uptake lesions (~2/patient) were segmented on PET images. Tumor PET response was assessed via the relative change in SUV(max), SUV(peak), SUV(mean), and SUV(total), thereby yielding 4 different responses for each tumor at mid- and posttreatment. For each SUV measure, a population average PET response was determined over all tumors. Standard deviation (SD) and range were used to quantify variation of PET response within individual tumors and population averages. RESULTS Different SUV measures resulted in substantial variation of individual tumor PET response assessments (average SD, 20%; average range, 40%). The most extreme variation between 4 PET response measures was 90% in individual tumors. Classification of tumor PET response depended strongly on the SUV measure, because different SUV measures resulted in conflicting categorizations of PET response (ambiguous treatment response assessment) in more than 80% of tumors. Variation of the population average PET response was considerably smaller (average SD, 7%; average range, 16%), and this variation was not statistically significant. Differences in tumor PET response were greatest between SUV(mean) and SUV(total) and smallest between SUV(max) and SUV(peak). Variations of tumor PET response at midtreatment and posttreatment were similar. CONCLUSION Quantification and classification of PET-based treatment response in individual patients were strongly affected by the SUV measure used to assess response. This substantial uncertainty in individual patient PET response was present despite the concurrent robustness of the population average PET response. Given the ambiguity of individual patient PET responses, selection of PET-based treatment response measures and their associated thresholds should be carefully optimized.
Collapse
|
257
|
Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med 2013; 54:677-82. [PMID: 23512357 DOI: 10.2967/jnumed.112.108530] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED (18)F-FDG PET qualitative tumor response assessment or tumor-to-background ratios compare targets against blood-pool or liver activity; standardized uptake value (SUV) semiquantitation has artifacts and is validated by a stable normal-tissue baseline. The aim of this study was to document the normal intrapatient range of scan-to-scan variation in blood-pool SUV and liver SUV and to identify factors that may adversely affect it (increase its spread). METHODS Between July 2009 and June 2010, 132 oncology patients had 2 PET/CT scans. Patient preparation, acquisition, and reconstruction protocols were held stable, uniform, and reproducible. Mean SUV (body weight) values were obtained from 2-dimensional regions of interest in the aortic arch blood pool and in the right lobe of the liver. RESULTS Of the 132 patients, 65 had lymphoma. Their mean age was 62.5 y. The group's mean serum glucose level was 6.0 mmol/L at the first visit and 5.9 mmol/L at the second visit. The mean (18)F-FDG dose was 4.1 MBq/kg at the first visit and 4.0 at the second. At the first visit, the group's mean blood-pool SUV was 1.55 (SD, 0.38); at the second, 1.58 (SD, 0.37)-not statistically different. The group's mean liver SUV was 2.17 (SD, 0.44) at the first visit and 2.29 (SD, 0.44) at the second (P = 0.005). Visit-to-visit intrapatient variation in blood-pool and liver SUVs had gaussian distributions. The variation in blood-pool SUV had a mean of 0.03 and SD of 0.42. The variation in liver SUV had a mean of 0.12 and SD of 0.50. Using 95th percentiles, the reference range in our patient population for intrapatient variation was -0.8 to 0.9 for blood pool SUV and -0.9 to 1.1 for liver SUV. Subanalysis by cancer type and chemotherapy suggested that the rise in liver SUV between the 2 visits was largely due to the commencement of chemotherapy, but no factors were identified as systematically affecting intrapatient variation, and no factors were identified as increasing its spread. CONCLUSION In our patient cohort, the reference range for intrapatient variation in blood-pool and liver SUVs is -0.8 to 0.9 and -0.9 to 1.1, respectively.
Collapse
|
258
|
Yang P, Xu XY, Liu XJ, Gong JS. The value of delayed (18)F FDG-PET imaging in diagnosis of solitary pulmonary nodules: A preliminary study on 28 patients. Quant Imaging Med Surg 2012; 1:31-4. [PMID: 23256051 DOI: 10.3978/j.issn.2223-4292.2011.11.03] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Accepted: 11/15/2011] [Indexed: 12/11/2022]
Abstract
OBJECTIVE The aim of this study was to investigate whether adding delayed phase imaging can improve diagnostic ability of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) in evaluating solitary pulmonary nodules (SPNs). MATERIALS AND METHODS 28 patients with SPNs received dual-phase (18)F-FDG PET at 1h and 2h after (18)F-FDG injection during Feb 2009 to Jun 2011were included in this retrospective study. Their final diagnosis was confirmed by pathological examination in 27 cases and clinical follow-up in 1 case. The standardized uptake value (SUV) of early and delayed phases of all lesions was measured. RESULTS The 28 SPNs included 9 benign lesions and 19 malignant lesions. Using SUV ≥2.5 as a criteria for malignancy, the sensitivity, specificity, and accuracy were 52.6%, 55.6% and 53.6% respectively at early phase; 68.4%, 55.6% and 64.3% respectively at early and delayed phases combined. Combined early and delayed phase scans combined picked up 3 additional malignant lesions from the 14 lesions with an initial SUV value less than 2.5, and there was no additional false positive result with the benign lesions. CONCLUSION Adding delayed phase scanning resulted in correct diagnosis of three malignant lesions with an initial SUV value less than 2.5. Delayed phase scanning can be recommended in the SPNs with SUV less than 2.5 at early phase.
Collapse
|
259
|
Lee SJ, Choi JY, Lee HJ, Baek CH, Son YI, Hyun SH, Moon SH, Kim BT. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma. Korean J Radiol 2012; 13:752-9. [PMID: 23118574 PMCID: PMC3484296 DOI: 10.3348/kjr.2012.13.6.752] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Accepted: 04/13/2012] [Indexed: 12/22/2022] Open
Abstract
Objective To evaluate the prognostic value of volume-based metabolic parameters measured with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in patients with clinically node-negative (cN0) oral tongue squamous cell carcinoma (OTSCC) as compared with other prognostic factors. Materials and Methods In this study, we included a total of 57 patients who had been diagnosed with cN0 tongue cancer by radiologic, 18F-FDG PET/CT, and physical examinations. The maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for primary tumors were measured with 18F-FDG PET. The prognostic significances of these parameters and other clinical variables were assessed by Cox proportional hazards regression analysis. Results In the univariate analysis, pathological node (pN) stage, American Joint Committee on Cancer (AJCC) stage, SUVmax, SUVavg, MTV, and TLG were significant predictors for survival. On a multivariate analysis, pN stage (hazard ratio = 10.555, p = 0.049), AJCC stage (hazard ratio = 13.220, p = 0.045), and MTV (hazard ratio = 2.698, p = 0.033) were significant prognostic factors in cN0 OTSCC patients. The patients with MTV ≥ 7.78 cm3 showed a worse prognosis than those with MTV < 7.78 cm3 (p = 0.037). Conclusion The MTV of primary tumor as a volumetric parameter of 18F-FDG PET, in addition to pN stage and AJCC stage, is an independent prognostic factor for survival in cN0 OTSCC.
Collapse
|
260
|
Genestreti G, Moretti A, Piciucchi S, Giovannini N, Galassi R, Scarpi E, Burgio MA, Amadori D, Sanna S, Poletti V, Matteucci F, Gavelli G. FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. J Cancer 2012; 3:241-5. [PMID: 22670158 PMCID: PMC3366479 DOI: 10.7150/jca.2586] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Accepted: 04/10/2012] [Indexed: 11/05/2022] Open
Abstract
PURPOSE Talc pleurodesis (TP) is employed worldwide for the management of persistent pneumothorax or pleural effusion, particularly of malignant origin. However, there are very little available data on (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography ((18)F FDG PET/CT) response evaluation in malignant pleural mesothelioma (MPM) patients treated with TP and chemotherapy. METHODS Patients with histologically confirmed MPM underwent TP and FDG PET/CT staging and restaging after 3-4 courses of chemotherapy. All patients fasted and received a dose of 5.18 MBq (18)F-FDG per kilogram of body weight. Whole-body emission scans were acquired with and without Ordered Subset Expectation Maximization (OSEM) iterative reconstruction algorithm. RESULTS From January 2004 to March 2010, 8 patients with biopsy confirmed MPM (7 epithelial, 1 biphasic), with a median age of 65 years (range: 54-77), were evaluated. Median follow-up was 31 months (range: 4-44). After TP treatment, there was a mean interval of 14 days (range: 9-22) and 125 days (range: 76-162) between FDG PET/CT staging and restaging. According to modified RECIST and EORTC criteria, there was a concordance between the radiologic and metabolic SUVmean and SUVmax responses in 6 (75%) and 3 (37.5%) patients, respectively. CONCLUSION TP produces an increased FDG PET uptake which may interfere with the post-chemotherapy disease evaluation. In our case series, the metabolic response measured by SUVmean seems to be in better agreement with the radiologic response compared to the SUVmax.
Collapse
|
261
|
Cavuşoğlu B, Durak H. The Effect of Patient Age on Standardized, Uptake Value-Hounsfield Unit Values of Male Genitourinery Structures In F-18 FDG PET/CT. Mol Imaging Radionucl Ther 2011; 20:104-7. [PMID: 23486855 PMCID: PMC3590953 DOI: 10.4274/mirt.40] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Accepted: 10/18/2011] [Indexed: 12/01/2022] Open
Abstract
Objective: Relation between patient age and Hounsfield Unit (HU),which is the linear attenuation coefficient, and Standardized Uptake Values (SUV) which is the amount of 18F-fluorodeoxyglucose (F-18 FDG) uptake, measured in the areas of interest drawn to prostate, seminal vesicles and testicles in F-18 FDG Positron Emission Tomography/Computed Tomography (PET/CT) images was investigated. Material and Methods: Mean and maximum SUV and HU values were recorded from the areas of interest (min 12 mm in diameter) which showed FDG uptake in prostate, seminal vesicles and testicles from F-18 FDG PET-CT images of 21 male patients under 40 years without genitourinary cancer. The effect of patient age to SUV and HU values was examined with Pearson correlation test using SPSS program. Results: There was a negative insignificant correlation between patient age and SUV and HU values for prostate. For seminal vesicles, correlation between patient age and SUV values and HUmax were positive but insignificant, while correlation with HUmean was significant (r=0.459, p=0.00). Correlation between patient age and SUVmax and SUVmean values were significant for testicles (r=0.506, p=0.002 and r=0.467, p=0.005, respectively) but the correlation between patient age and HUmax and HUmean values was not significant. Conclusion: F-18 FDG uptake in testicles in males increases with age until 40, suggesting an increase in metabolic rate. The significant correlation between age and mean HU values is probably caused by thickening of the tissue without an increase in glucose metabolism in seminal vesicles. In prostate, the effect of patient age to SUV and HU values was not observed until the age 40. Conflict of interest:None declared.
Collapse
|
262
|
(18)F-FDG Uptake of Human Testis on PET/CT: Correlation with Age, Sex Hormones, and Vasectomy. Nucl Med Mol Imaging 2011; 45:291-8. [PMID: 24900020 DOI: 10.1007/s13139-011-0108-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2010] [Revised: 08/17/2011] [Accepted: 08/26/2011] [Indexed: 10/17/2022] Open
Abstract
PURPOSE The purpose of this study was to evaluate glucose metabolism of normal human testis on (18)F-FDG PET/CT and to assess possible correlations among age, the serum levels of sex hormones, and vasectomy. METHODS (18)F-FDG PET/CT was performed in 66 normal healthy men (50.8 ± 13.6 years, range 22-81), and mean standard uptake values (SUV) of (18)F-FDG in testis and adductor muscle were measured. Testis-muscle SUV ratios (T/M ratios) were calculated. Serum levels of total testosterone, free testosterone, estradiol, and of sex-hormone binding globulin (SHBG) were measured. We searched for correlations between T/M ratios and age and the serum concentrations of sex hormones. (18)F-FDG PET/CT was also performed in 32 vasectomized men (55.7 ± 7.8 years, range 38-71) and 52 nonvasectomized men (55.4 ± 11.6 years, range 37-72). Mean SUVs of testis and adductor muscle were measured, and T/M ratios were calculated. RESULTS A significant age-related decline was found in T/M ratio (r = -0.509, p < 0.0001). Serum levels of total testosterone and free testosterone were also found to be positively correlated with T/M ratio (r = 0.427, p = 0.0003; r = 0.435, p = 0.0003, respectively). The mean SUV and T/M ratio of vasectomized men were significantly lower than those of nonvasectomized men (p < 0.0378 and p = 0.0001, respectively). CONCLUSIONS Glucose metabolism in the testis in an adult population was found to be correlated with age, serum sex hormone level, and vasectomy history. These results indicate that testicular (18)F-FDG uptake may have attributed to testicular function and testicular histology. Our findings may have important implications for the interpretation of testicular (18)F-FDG uptake in the normal adult population.
Collapse
|
263
|
Nguyen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, Kim SE. Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nucl Med Mol Imaging 2010; 44:39-44. [PMID: 24899936 DOI: 10.1007/s13139-009-0009-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Revised: 11/02/2009] [Accepted: 11/16/2009] [Indexed: 11/26/2022] Open
Abstract
PURPOSE It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The authors undertook this study to determine whether a parameter that reflects both FDG uptake magnitude and the greatest tumor diameter is a prognostic indicator in DLBCL. MATERIALS AND METHODS Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17; stage I/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled. A lesion with the highest maximum standardized uptake value (MaxSUV) on the PET image was selected, and size-incorporated MaxSUV (SIMaxSUV) of mass was calculated as MaxSUV × greatest diameter (mm) on the transaxial PET image. Median follow-up duration was 20.0 months. RESULTS Twelve (28.6% = 12/42) patients experienced disease progression, and 10 (23.8% = 10/42) died during follow-up. Among six variables [Ann Arbor stage, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05). CONCLUSION These results suggest that SIMaxSUV, a new FDG-PET parameter that incorporates FDG uptake magnitude and the greatest tumor diameter, may be a useful indicator of prognosis in untreated DLBCL.
Collapse
|
264
|
Abstract
After diagnosis and staging of cancer, the most important process in modern oncology is assessment of therapeutic response. Timely identification of patients with poor response may allow introduction of alternative therapies, sparing patients the toxicity of ineffective treatments, reducing health care cost, and potentially delivering better outcomes. Metabolic imaging using PET is increasingly recognized as providing earlier and more robust assessment than conventional imaging. There are now ample clinical data indicating that PET metabolic response should be strongly considered for inclusion in evaluation of clinical response in individual high-risk malignancies to both direct the care of individual patients and to guide application of new therapies in particular cancer populations.
Collapse
|